Extended-Release Quetiapine Fumarate (Quetiapine Xr) as Adjunctive Therapy in Patients with Generalized Anxiety Disorder and A history of Inadequate Treatment Response: A Randomized,Double-Blind Study
Restricted accessResearch articleFirst published online February, 2014
Extended-Release Quetiapine Fumarate (Quetiapine Xr) as Adjunctive Therapy in Patients with Generalized Anxiety Disorder and A history of Inadequate Treatment Response: A Randomized,Double-Blind Study
For many patients with generalized anxiety disorder (GAD), first-line treatment does not lead to remission. This study investigated the efficacy and tolerability of adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with GAD and an inadequate response to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
Methods
Patients were randomized to quetiapine XR or placebo adjunctive to SSRI/SNRIs in an 11-week study. The primary endpoint was change from randomization to week 8 in Hamilton Anxiety Rating Scale (HAM-A) total score. Secondary variables were HAM-A psychic/somatic clusters, response, and remission, and Clinical Global Impression–Severity of Illness (CGI-S) score.
Results
A total of 409 patients received quetiapine XR (n = 209) or placebo (n = 200). The week 8 mean change in HAM-A total score was not statistically significant for quetiapine XR (–10.74; P = .079) vs placebo (–9.61). Secondary variables were generally consistent with the primary analysis, except for a significant reduction in HAM-A total score (week 1) and significant improvements in HAM-A psychic cluster and CGI-S total scores (week 8). Adverse events included dry mouth, somnolence, sedation, headache, and dizziness.
Conclusions
In patients with GAD and an inadequate response to SSRI/ SNRIs, adjunctive quetiapine XR did not show a statistically significant effect for the primary endpoint at week 8, although some secondary end-points were statistically significant vs placebo. Quetiapine XR was generally well tolerated.
BruceSE, YonkersKA, OttoMW, . Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry.2005;162:1179–1187.
WittchenHU.Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety.2002;16:162–171.
4.
BaldwinDS, AndersonIM, NuttDJ, . Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol.2005;19:567–596.
5.
BandelowB, ZoharJ, HollanderE, ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry.2008;9:248–312.
6.
Canadian Psychiatric Association. Management of anxiety disorders. Can J Psychiatry.2006;51:(8 suppl 2)1S–93S.
7.
NICE guidelines.Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. http://www.nice.org.uk/CG022NICEguidelines. Accessed April 1, 2010.
8.
RickelsK, RynnM, IyengarM, . Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry.2006;67:41–47.
9.
MontgomerySA, SheehanDV, MeoniP, . Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res.2002;36:209–217.
10.
KatzmanMA, VermaniM, JacobsL, . Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord.2008;22:1480–1486.
11.
LohoffFW, EtemadB, MandosLA, . Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol.2010;30:185–189.
12.
BandelowB, ChouinardG, BobesJ, . Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol.2010;13:305–320.
13.
KhanA, JoyceM, AtkinsonS, . A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol.2011;31:418–428.
14.
MeridethC, CutlerAJ, SheF, . Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo-controlled and active-controlled study. Int Clin Psychopharmacol.2012;27:40–54.
15.
MezhebovskyI, MagiK, SheF, . Double-blind, randomized study of extended release quetiapine fuma-rate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry.2013;28:615–625.
16.
KatzmanMA, Brawman-MintzerO, ReyesEB, . Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol.2011;26:11–24.
Seroquel [package insert]. Wilmington, DE: AstraZeneca; 2013.
19.
Diagnostic and statistical manual of mental disorders, 4th edition.Washington, DC: American Psychiatric Association;1994.
20.
SheehanDV, LecrubierY, SheehanKH, . The Mini-International Neuropsychiatric Interview (M. I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry.1998;59:(suppl 20)22–33.
21.
HamiltonM.The assessment of anxiety states by rating. Br J Med Psychol.1959;32:50–55.
22.
GuyW.Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology.Washington, DC: US Department of Health, Education and Welfare; 1976:218–222.
23.
EndicottJ, NeeJ, HarrisonW, . Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull.1993;29:321–326.
24.
PosnerK, OquendoMA, GouldM, . Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry.2007;164:1035–1043.
25.
SimpsonGM, AngusJWS.A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand Suppl.1970;212:11–19.
26.
BarnesTR.A rating scale for drug-induced akathi-sia. Br J Psychiatry.1989;154:672–676.
HommelG.A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika.1988;75:383–386.
30.
PinsonL, GrayGE.Psychopharmacology: number needed to treat: an underused measure of treatment effect. Psychiatr Serv.2003;54:145–146.,154.
31.
RynnMA, Brawman-MintzerO.Generalized anxiety disorder: acute and chronic treatment. CNS Spectr.2004;9:716–723.
32.
KhanA, KhanS, BrownWA.Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol.2002;5:193–197.
33.
FavaM, EvinsAE, DorerDJ, . The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom.2003;72:115–127.
34.
KatzMM, HalbreichUM, BowdenCL, . Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants. Neuropsychopharmacology.2002;27:319-328.
35.
Brawman-MintzerO, KnappRG, NietertPJ.Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry.2005;66:1321–1325.
36.
LydiardRB, RickelsK, HermanB, . Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol.2010;13:229-241.
37.
BauerM, PretoriusHW, ConstantEL, . Extended-release quetiapine as adjunct to an antide-pressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry.2009;70:540–549.
38.
BortnickB, El-KhaliliN, BanovM, . Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord.2011;128:83–94.
39.
CutlerAJ, MontgomerySA, FeifelD, . Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry.2009;70:526–539.
40.
El-KhaliliN, JoyceM, AtkinsonS, . Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol.2010;13:917–932.
41.
WeislerR, JoyceM, Mc GillL, . Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr.2009; 14:299–313.
42.
PurdonSE, MallaA, LabelleA, . Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci.2001;26:137–149.
43.
LiebowitzM, LamRW, LepolaU, . Efficacy and tolerability of extended release quetiapine fuma-rate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety.2010;27:964–976.
44.
NybergS, WidzowskiD.Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties. Eur Psychiatry.2010;25:(suppl 1)1446.
45.
JensenNH, RodriguizRM, CaronMG, . N-desalkylquetiapine, a potent norepinephrine reup-take inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology.2008;33:2303–2312.
46.
OwensMJ, KrulewiczS, SimonJS, . Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology.2008;33: 3201–3212.
47.
ArvanitisLA, MillerBG.Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry.1997;42:233–246.
48.
KahnRS, SchulzSC, PalazovVD, . Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry.2007;68:832–842.
49.
TimdahlK, CarlssonA, SteningG.An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol.2007;22:315–325.
